Medicines & Treatments
GHK Basic 50 mg
GHK Basic 50 mg – Peptide Hubs GHK (Glycyl-L-Histidyl-L-Lysine) is a naturally occurring copper-binding peptide well-regarded for its powerful tissue-repairing, anti-aging, and regenerative effects. The "Basic" variant offered by Peptide Hubs provides 50 mg of high-purity GHK in a lyophilized 2 mL vial, ideal for advanced research into skin regeneration, wound healing, and cellular rejuvenation. What Is GHK Basic? GHK is a tripeptide with the unique ability to bind copper ions (Cu2+), forming GHK-Cu, which has been shown to stimulate collagen production, support wound healing, modulate inflammation, and enhance hair and skin regeneration. While GHK-Cu is widely known, studies show that the GHK base peptide also exhibits profound biological activity on its own, particularly in gene expression and tissue remodeling. Mechanism of Action GHK modulates over 4,000 human genes, many of which are involved in inflammation reduction, tissue remodeling, antioxidant defense, and stem cell stimulation. It promotes fibroblast proliferation, improves angiogenesis, and enhances skin elasticity and firmness. For further context, see this NIH review on GHK peptide and its regenerative potential.
GHK-Cu 10 mg
Lab-Tested GHK-CU 10mg by Dragon Pharma – Advanced Peptide for Skin Health & Cellular Repair GHK-CU 10mg by Dragon Pharma is a powerful copper peptide known for its regenerative properties, particularly in skin rejuvenation, wound healing, and inflammation reduction. Each 2 mL vial delivers 10 mg of GHK-CU in a stable lyophilized form, manufactured under strict quality control and independently lab-tested for purity and concentration. What is GHK-CU and Why It Matters? GHK-CU is a naturally occurring peptide complex (glycyl-L-histidyl-L-lysine bound to copper) with profound effects on tissue remodeling and repair. It plays a key role in activating genes responsible for collagen synthesis, skin regeneration, and anti-inflammatory pathways—making it especially popular in the fields of biohacking, anti-aging, and aesthetics.
FOXO4-DRI 10 mg
Dragon Pharma FOXO4-DRI 10 mg – Experimental Senolytic Peptide for Senescence Research ✔ Selective senescent cell clearance ✔ FOXO4-p53 pathway inhibitor ✔ Studied for anti-aging mechanisms ✔ USA domestic shipping available Dragon Pharma FOXO4-DRI 10 mg is an experimental senolytic peptide designed to selectively target and eliminate senescent cells, commonly referred to as "zombie" cells. This peptide functions by blocking the interaction between the FOXO4 and p53 proteins, a mechanism that has been investigated in preclinical studies for its potential to reduce age-related markers and improve physical function. Each vial contains 10 mg of lyophilized FOXO4-DRI in a 2 mL format, requiring reconstitution with bacteriostatic water before use. FOXO4-DRI represents a targeted research tool for investigating cellular senescence, aging processes, and potential therapeutic interventions. For related research compounds, explore our peptides category and specifically Epitalon 50 mg for complementary longevity research applications. What Makes FOXO4-DRI Valuable in Research? FOXO4-DRI is a rationally designed peptide that specifically disrupts the FOXO4-p53 interaction, which is critical for senescent cell survival. By interfering with this protein-protein interaction, FOXO4-DRI triggers apoptosis selectively in senescent cells while leaving healthy cells unaffected. This targeted approach has demonstrated promising results in preclinical mouse models, showing reduced senescence markers and improved physical performance. Researchers value FOXO4-DRI for its specificity and the mechanistic insights it provides into cellular senescence pathways. Its ability to selectively clear senescent cells makes it a valuable tool for investigating the role of senescence in aging, tissue dysfunction, and age-related diseases. For investigators exploring cellular protection mechanisms, SS-31 50 mg offers complementary research avenues in mitochondrial function and cellular health. Current scientific literature on FOXO4-DRI and senolytic research can be accessed through the PubMed database, where researchers can review peer-reviewed studies on its biological activity and experimental applications. Key Research Applications for Dragon Pharma FOXO4-DRI ✔ Investigation of cellular senescence mechanisms ✔ Evaluation of senolytic activity in various tissue types ✔ Research on aging and age-related pathologies ✔ Studies of tissue regeneration following senescence clearance ✔ Preclinical models of physical function and recovery For Research Purposes Only FOXO4-DRI 10 mg is intended for research use only and is not approved for human consumption. Proper handling, reconstitution, and experimental protocols are essential for reliable results. For studies on regenerative peptides, BPC 157 provides additional research avenues in tissue repair mechanisms.
